Drugs

Article	Citations
Prevention and Treatment of Monkeypox	356
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	257
BNT162b2 mRNA COVID-19 Vaccine: First Approval	253
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences	220
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin	218
Inclisiran: First Approval	208
Lumasiran: First Approval	187
Nirmatrelvir Plus Ritonavir: First Approval	179
Acute Pancreatitis: Diagnosis and Treatment	176
Casimersen: First Approval	164
Aducanumab: First Approval	156
Sotorasib: First Approval	132
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile I	125
TRPV1-Targeted Drugs in Development for Human Pain Conditions	120
Setmelanotide: First Approval	111
Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing	110
Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update	110
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects	102
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis	101
Nivolumab Plus Relatlimab: First Approval	89
Orelabrutinib: First Approval	86
REGN-EB3: First Approval	85
Deucravacitinib: First Approval	84
Amivantamab: First Approval	82
Lonafarnib: First Approval	81

Remimazolam: A Review in Procedural Sedation	80
Fabry Disease: The Current Treatment Landscape	78
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder	78
Belzutifan: First Approval	75
Faricimab: First Approval	75
Abrocitinib: First Approval	71
Savolitinib: First Approval	70
Pralsetinib: First Approval	70
Disitamab Vedotin: First Approval	70
Vutrisiran: First Approval	69
Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain	67
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases	66
Tisotumab Vedotin: First Approval	65
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations	64
Molnupiravir: First Approval	63
Cadonilimab: First Approval	63
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics	62
MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19	61
Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections	60
Telitacicept: First Approval	60
Casirivimab/Imdevimab: First Approval	60
Current Status of Clinical Trials on Tau Immunotherapies	60
Trilaciclib: First Approval	60
Efgartigimod: First Approval	59
Contezolid: First Approval	58
Targeting AMPK by Statins: A Potential Therapeutic Approach	57
Lecanemab: First Approval	57
Loncastuximab Tesirine: First Approval	57
Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis	57
Infigratinib: First Approval	57
Tebentafusp: First Approval	57
Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections	56
Ocrelizumab: A Review in Multiple Sclerosis	55
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update	55
Tirzepatide: First Approval	55
Envafolimab: First Approval	55
Dostarlimab: First Approval	54
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals	54
Pegcetacoplan: First Approval	53
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations	52
Umbralisib: First Approval	52
Nirsevimab: First Approval	50
Filgotinib: First Approval	50
Tremelimumab: First Approval	50
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective	50
Donafenib: First Approval	49
Naxitamab: First Approval	49
Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents	47
Anifrolumab: First Approval	47
Fuzuloparib: First Approval	47

Delandistrogene Moxeparvovec: First Approval	47
Odevixibat: First Approval	47
Mavacamten: First Approval	46
Teclistamab: First Approval	46
Regdanvimab: First Approval	46
Therapeutic Options in Hereditary Optic Neuropathies	46
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review	46
Givosiran: A Review in Acute Hepatic Porphyria	46
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review	45
Mirvetuximab Soravtansine: First Approval	45
Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists	45
Adagrasib: First Approval	44
Androgenetic Alopecia: Therapy Update	44
Lazertinib: First Approval	44
Tezepelumab: First Approval	43
Valoctocogene Roxaparvovec: First Approval	43
Spesolimab: First Approval	43
Etranacogene Dezaparvovec: First Approval	42
Voclosporin: First Approval	42
Sotrovimab: First Approval	41
Mosunetuzumab: First Approval	41
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes	41
Pamiparib: First Approval	40
Daridorexant: First Approval	40
Avacopan: First Approval	40
Melphalan Flufenamide (Melflufen): First Approval	39
Asciminib: First Approval	39
Finerenone: First Approval	39
Vericiguat: First Approval	39
Pacritinib: First Approval	38
Mobocertinib: First Approval	38
Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents	38
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A	38
Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions	37
Tixagevimab + Cilgavimab: First Approval	37
Lenacapavir: First Approval	37
REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study	37
Evinacumab: First Approval	37
Olverembatinib: First Approval	36
Ibrexafungerp: First Approval	36
Futibatinib: First Approval	36
Margetuximab: First Approval	36
Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy	36
Ansuvimab: First Approval	36
Tofersen: First Approval	36
Atogepant: First Approval	36
Ozoralizumab: First Approval	36
Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?	35
Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis	34
Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)	34
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease	33
Maralixibat: First Approval	33
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa	33
Tapinarof Cream 1%: First Approval	32
Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies	31
Difelikefalin: First Approval	31
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets	30
Belumosudil: First Approval	30
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification	30
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?	30
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	30
The Potential Role of Clinical Metagenomics in Infectious Diseases: Therapeutic Perspectives	30
Omaveloxolone: First Approval	30
Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC	30
Pimitespib: First Approval	30
Hetrombopag: First Approval	29
Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry	29
Oteseconazole: First Approval	29
Nemolizumab: First Approval	29
Ocular Toxicity of Targeted Anticancer Agents	28
Tralokinumab: First Approval	28
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	28
Ganaxolone: First Approval	28
Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside	27
The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density	27
Secukinumab: A Review in Psoriatic Arthritis	27
Ritlecitinib: First Approval	27
Enarodustat: First Approval	26
Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review	26
Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review	26

Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients	26
Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis	26
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence	26
Avatrombopag: A Review in Thrombocytopenia	26
The Role of Vitamin D in Health and Disease: A Narrative Review on the Mechanisms Linking Vitamin D with Disease and the Effects of Supplementation	25
Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia	25
Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors	25
The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of Tuberculosis	25
Furmonertinib: First Approval	24
Nadofaragene Firadenovec: First Approval	24
Benefits and Harms of ‘Smart Drugs’ (Nootropics) in Healthy Individuals	24
Maribavir: First Approval	24
Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease	24
Contemporary Management of Dyslipidemia	24